Related Experiment Video

Updated: May 19, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prostate cancer vaccines in clinical trials

David M Lubaroff1

  • 1Department of Urology, University of Iowa Carver College of Medicine and The Holden Comprehensive Cancer Center, 375 Newton Road, 3210 MERF, Iowa City, IA 52242, USA. david-lubaroff@uiowa.edu

Expert Review of Vaccines
|August 24, 2012
PubMed

Insights

This review covers prostate cancer vaccine immunotherapy, including Sipuleucel-T (prostatic acid phosphatase vaccine) and Prostvac-TRICOM (prostate-specific antigen vaccine). It examines preclinical data and challenges in developing effective prostate cancer immunotherapies.

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Prostate cancer immunotherapy is an evolving field.
  • Several therapeutic vaccines targeting prostate cancer have been developed and tested in clinical trials.
  • Understanding immune regulation is crucial for effective cancer vaccines.

Purpose of the Study:

  • To review the current state of prostate cancer vaccine immunotherapy.
  • To present preclinical research for key prostate cancer vaccines in clinical trials.
  • To discuss the benefits, concerns, and immune challenges associated with these therapies.

Main Methods:

  • Review of preclinical data for prostate cancer vaccines.
  • Analysis of clinical trial outcomes for approved and investigational vaccines.
  • Examination of immune regulatory mechanisms in prostate cancer.

Main Results:

  • Sipuleucel-T, targeting prostatic acid phosphatase (PAP), is the only FDA-approved prostate cancer vaccine.
  • Prostvac-TRICOM (prostate-specific antigen - PSA) is in Phase III trials.
  • Other vaccines like Ad5-PSA and DNA-PAP are in development, with GVAX cellular vaccine having intermittent study.

Conclusions:

  • Significant progress has been made in prostate cancer vaccine immunotherapy.
  • Overcoming immune evasion is critical for enhancing vaccine efficacy.
  • Further research is needed to optimize immune responses against prostate tumors.

More Related Videos

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Vaccinations01:51

Vaccinations

Overview